Evaluation of Immunoglobulins, CD4/CD8 T Lymphocyte Ratio and Interleukin-6 in COVID-19 Patients

Abstract

Introduction: The outbreak of novel coronavirus COVID-19 infections that started in China late 2019 has spread rapidly and cases have been recorded worldwide. So, in this study, we sought clarification of the clinical characteristics and importance of changing the lymphocyte group, antibodies, CD markers, and interleukin-6 in the serum of COVID-19 patients, which may help to clarify the pathogen and develop new biomarkers. Material and Methods: Venous blood samples had been accumulated from patients before taking any medications. Sera had been separated and saved at (-20°C) until analysis. Serum anti-SARS-CoV-2 immunoglobulins (IgG, IgA, and IgM) were determined in plasma samples using enzyme-linked immunosorbent assays (ELISA) and Serum IL-6 was assessed. Results: Median IgM (p=0.001), IgG (p<0.0001), and IgA (p<0.001), were decreased in patients comparing with control the control group. There is a significant decrease in CD3+ and CD4+ cells compared to healthy individuals in patients infected with COVID-19 (p<0.0001). CD19+ cell count decreased in COVID-19 patients compared to that of the control group (p<0.0001). After calculating CD4+/CD8+ cell ratio decreased in COVID-19 patients (p<0.0001). However, CD56+ cells were found to be increased (p<0.0001). Conclusions: IgM, IgG, IgA levels and CD19+, CD4+ cells, CD4+/CD8+ cell ratio were found to be decreased whereas CD8+, CD3+, CD4+ cells were detected to be increased in COVID-19 patients compared to those of healthy controls. Keywords: IL-6, COVID-19, IgG, IgA, IgM, CD markers

RETRACTED ARTICLE: Evaluation of ferritin level in COVID-19 patients and its inflammatory response

“…The researchers added that the frequency of different cell types might be influenced by several factors, including age, gender, sickness, and medications. According to research (Mao et al 2020;Saleh et al 2020), White WBC count and peripheral blood lymphocytes are normal or slightly decreased in the early stages of COVID-19 infection, when patients have no symptoms, but these markers may change as the disease progresses. In a study of 140 hospitalized patients diagnosed with COVID-19 based on CT scan results, Zhang et al found that the leukocyte count was within normal limits in 68.1% of patients diagnosed with COVID-19, which is increased in 12.3% of patients, and decreased in 19.6% of patients.…”

RETRACTED ARTICLE: Serum level estimation of some biomarkers in diabetic and non-diabetic COVID-19 infected patients

“…Cough, shortness of breath, and fever are the most prevalent medical signs (Huang et al 2020), as are gastrointestinal symptoms such as nausea, vomiting, abdominal pain, increased total serum bilirubin levels, and elevated liver enzymes like GOT and GPT (Huang et al 2020;Cheung et al 2020). The significance of numerous symptoms, comorbidities, inflammation, and hypercoagulability indicators in disease progression and mortality in COVID-19 patients is becoming clearer (Saleh et al 2020;Moghadasi et al 2021;Jalil et al 2020Jalil et al , 2021aDilfy et al 2020;Marofi et al 2021a;Widjaja et al 2021;Turki Jalil et al 2021;Sarjito et al 2021;Jalil 2020). Diabetes, one of the main causes of morbidity, has been found to have a high prevalence and is linked to adverse disease progression in COVID-19 (Li et al 2020a;Guo et al 2020).…”

Molecular study of quorum sensing and biofilm formation genes in pseudomonas aeruginosa isolated from UTIs patients

“…A study in Iraq reported nearly similar results, where the resistant rates for penicillin antibiotics including ticarcillin, piperacillin and minocycline and trimethoprim+ sulfamthoxazole were 76.7%, 81.0%, 91.0% and 93.5%, respectively (26). Also, Abdul-Wahid, (24,(40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(50)(51) in Iraq reported similar results where the resistant rates for ceftazidime, cefepime, ciprofloxacin, pefloxacin, gentamicin and aztreonam (64.0%, 63.5%, 59.0%, 58.5%, 63.0% and 57.0%), respectively. While, the other study in Iraq by Alkazrage (27) reported the resistant rates for imipenem, meropenem and colistin (35.0%, 31.0% and 21.8%), respectively.…”